Risk Managemen Case Discussion: Young Again Pharmaceuticals

Risk Management
Case 9-1 discusses Young Again Pharmaceuticals.
So as to be clear this will be a 2-page paper addressing 2 related questions.
CASE 9-1
Young Again Pharmaceuticals Cliff Crandall, senior director of transportation for Young Again Pharmaceuticals (YAP), is gearing up for his company's most critical product rollout in more than a
decade. YAP has developed a breakthrough liquid suspension that reverses the aging process for anyone over 35 years of age. Available only by prescription, the new product has been dubbed “Twenty-something in a Bottle” by the media. Demand is expected to be very high despite the outlandish price tag of $395 for a month's supply.  The product is being manufactured in YAP's San Juan, Puerto Rico laboratory and will be distributed to major retail pharmacies in the United States and Canada. Crandall is responsible for selecting the mode and contracting with carriers to deliver the  product. He is concerned about the safe and timely delivery of the initial product shipments in May to the retailers' distribution centers. The product is high value, somewhat fragile, and of interest to thieves. Some product, stolen from the laboratory, has already appeared on auction websites. In an effort to make effective transportation decisions and minimize YAP's risks, Crandall decided to hold a brainstorming session with his logistics team before signing any carrier contracts. The discussion of key risks produced the following list of
concerns:
• “If shipments are late or incomplete, retailers will penalize us with vendor
chargebacks. You know they will hit us with small fines for delivery
mistakes.”
• “I'm worried about shipment delays or freight loss from hurricanes in the
Atlantic Ocean.”
• “You've got to consider temperature sensitivity issues. If the product freezes,
we won't be able to sell it.”
• “I've been reading about all the piracy problems experienced by ocean carriers.
You know, a 20-foot container of our product has a retail value of nearly $275,000.”
• “I'm more concerned about theft of individual cases at ports and while the product is on the road.”
• “We're looking at border delays and Customs fines if we don't properly document and mark our freight.”
• “Our brand image will take major damage if the product gets into unauthorized distribution channels due to theft or misdirected deliveries.”
• “The company sustainability push has led to reduced packaging and biodegradable packing materials. If the cartons get wet or bounced around, we're going to end up with a lot of damaged, unsellable product.”
• “Those major East Coast ports can get very congested during peak shipping season. That will cause delays.”
By the time the meeting was over, Crandall realized that he needed to spend some time looking into these issues. While he was pretty sure that some problems were remote, Crandall thought that it would be wise to evaluate each one. His new concern became how to conduct an effective risk assessment. The three options that this firm has to manage risk are risk retention, risk transfer, or a mixed approach. In 200 – 250 words, discuss your recommendations on how this company should evaluate and implement these techniques to manage risks. I would like to add another question related to the first one thus page requirement from 1 to 2
Please answer the question separately.
Given your answer to Discussion Forum 1, What do you believe Young Again Pharmaceuticals should focus on once the risks are mitigated.
One text to use for citation
Coyle, J., Novack, R.A., Gibson, B.J., & Barbi, E.J. (2011). Transportation: A Supply Chain Perspective (7th ed). Mason, OH: South-Western Cengage Learning. ISBN: 978-0-324-78919-5